Tag: Data integrity

Addressing Weak System Access Controls During Upgrades to Prevent Part 11 Findings The pharmaceutical industry is continuously advancing, particularly with the integration of electronic recordkeeping systems. However, these upgrades can…

Addressing Misuse of Electronic Signatures During System Upgrades: A Regulatory Playbook The use of electronic signatures (e-signatures) is a fundamental aspect of regulatory compliance in pharmaceutical manufacturing, especially during system…

Strategies for Managing Record Retention Failures During System Upgrades In the ever-evolving landscape of pharmaceutical manufacturing, the integrity of electronic records is paramount. Record retention failures during a system upgrade…

Managing ERES Controls Lapses During Compliance Audits: Your Playbook In an increasingly regulated environment, pharmaceutical manufacturers face mounting pressure to ensure robust compliance with Electronic Records and Electronic Signatures (ERES)…

Remediation for ERES Control Failures During System Operation In the evolving landscape of pharmaceutical manufacturing, the implementation of effective electronic records and electronic signatures (ERES) controls is critical. When ERES…

Strengthening System Access Controls During Upgrades: An Inspection-Ready Playbook Pharmaceutical manufacturers frequently confront challenges when upgrading electronic systems. A particularly critical issue arises when system access controls are weak during…

Handling Incomplete ERES Controls During Inspection Walkthroughs: A Comprehensive Playbook The pharmaceutical industry is under increasing scrutiny for the management of Electronic Records and Electronic Signatures (ERES). When ERES controls…

Managing Hybrid Paper-Electronic Workflows: Tactics for Compliance During Inspections The increasing integration of hybrid paper-electronic workflows has created new challenges in regulatory compliance. Specifically, 21 CFR Part 11 requirements for…

Implementing Effective Controls to Prevent ERES System Operation Failures The increasing reliance on electronic records and electronic signatures (ERES) in the pharmaceutical industry underscores the importance of robust controls. ERES…

Risk-Based Remediation for Inadequate ERES Controls During System Upgrade In the rapidly evolving landscape of pharmaceutical compliance, the implementation of Electronic Records and Electronic Signatures (ERES) controls during system upgrades…

Managing Uncontrolled Hybrid Paper-Electronic Workflows During Validation Lifecycle As digital transformation accelerates within pharmaceutical manufacturing, uncontrolled hybrid paper-electronic workflows pose significant regulatory compliance risks, particularly concerning 21 CFR Part 11.…

Mitigating Misuse of Electronic Signatures During Inspection Walkthroughs: A Comprehensive Playbook The increasing reliance on electronic signatures in the pharmaceutical sector brings both efficiency and regulatory challenges, particularly during inspection…